ArticleThoracic cancer2018

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.

Zhansheng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.